SCHEMBL3634142

SCHEMBL3634142

COc1cccc(F)c1C(C(=O)NNc1cc(C(F)(F)F)cc(C(F)(F)F)c1)N1CCN(C)CC1

nearest known ligand 0.61

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
GHSR Q92847 2/20 0.61
CCR3 P51677 1/20 0.45
TACR1 P25103 5/20 0.40
HTR1A P08908 2/20 0.40
HTR1D P28221 2/20 0.40
HTR1B P28222 2/20 0.40
HTR2C P28335 2/20 0.40
HTR6 P50406 2/20 0.40
RXFP1 Q9HBX9 2/20 0.39
HTR2A P28223 1/20 0.38
LMNA P02545 5/20 0.38
SMN1; SMN2 Q16637 3/20 0.38
HTT P42858 2/20 0.38
TP53 P04637 1/20 0.37
MAPT P10636 1/20 0.37
P2RX1 P51575 1/20 0.37
P2RX7 Q99572 1/20 0.37
TRPA1 O75762 1/20 0.37
KMT2A Q03164 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13078475 0.92 GHSR (0.53) GHSRCCR3TACR1HTR1AHTR1D
SCHEMBL3637403 0.91 GHSR (0.68) GHSRCCR3TACR1LMNAP2RX1
SCHEMBL3635557 0.87 GHSR (0.77) GHSRCCR3TACR1HTR1AHTR1D
SCHEMBL13078454 0.83 GHSR (0.58) GHSRCCR3TACR1LMNASMN1; SMN2
SCHEMBL3639974 0.83 GHSR (0.74) GHSRTACR1LMNASMN1; SMN2P2RX1
SCHEMBL3638153 0.82 GHSR (0.80) GHSRTACR1KMT2A
SCHEMBL13078455 0.79 GHSR (0.66) GHSRCCR3TACR1
SCHEMBL3635203 0.79 GHSR (0.74) GHSRCCR3TACR1RXFP1
SCHEMBL3634225 0.79 GHSR (0.67) GHSRCCR3TACR1LMNASMN1; SMN2
SCHEMBL3638183 0.77 GHSR (0.71) GHSRCCR3TACR1LMNASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100286152-A1 N-PHENYL HYDRAZIDES AS MODULATORS OF THE GHRELIN RECEPTOR GLAXO GROUP LIMITED (GB) 2010-11-11 US claimed
EP-2167466-A1 N-PHENYL HYDRAZIDES AS MODULATORS OF THE GHRELIN RECEPTOR Glaxo Group Limited (GB) 2010-03-31 EP claimed
WO-2008148853-A1 N-PHENYL HYDRAZIDES AS MODULATORS OF THE GHRELIN RECEPTOR GLAXO GROUP LIMITED (GB) 2008-12-11 WO claimed
US-20100286152-A1 N-PHENYL HYDRAZIDES AS MODULATORS OF THE GHRELIN RECEPTOR GLAXO GROUP LIMITED (GB) 2010-11-11 US disclosed
US-20100286152-A1 N-PHENYL HYDRAZIDES AS MODULATORS OF THE GHRELIN RECEPTOR GLAXO GROUP LIMITED (GB) 2010-11-11 US disclosed
EP-2167466-A1 N-PHENYL HYDRAZIDES AS MODULATORS OF THE GHRELIN RECEPTOR Glaxo Group Limited (GB) 2010-03-31 EP disclosed
WO-2008148853-A1 N-PHENYL HYDRAZIDES AS MODULATORS OF THE GHRELIN RECEPTOR GLAXO GROUP LIMITED (GB) 2008-12-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100286152-A1 N-PHENYL HYDRAZIDES AS MODULATORS OF THE GHRELIN RECEPTOR GIPR, GHSR, GLP1R GHSR 2/4885CCR3 3769/4885TACR1 56/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.